Seres Therapeutics Inc. (NASDAQ: MCRB) announced preclinical data for SER-603, a live biotherapeutic candidate for inflammatory bowel disease, at Digestive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE